BM 06.022: A Novel Recombinant Plasminogen Activator

Cardiovascular Drug Reviews

Volumn 11, Issue 3, 1993, Pages 299-311

  Martin, Ulrich ^a   Bader, Rainer ^a   Böhm, Erwin ^a   Kohnert, Ulrich ^a   von Möllendorf, Erika ^a   Fischer, Stephan ^a   Sponer, Gisbert ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

BM 06.022; Myocardial infarction; Plasminogen activator; Thrombolysis

Indexed keywords

ALTEPLASE; ANISTREPLASE; FIBRIN; FIBRINOLYTIC AGENT; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; RECOMBINANT PLASMINOGEN ACTIVATOR; RETEPLASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

AMES TEST; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD CLOT LYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY RECANALIZATION; CORONARY ARTERY THROMBOSIS; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; JUGULAR VEIN; LUNG EMBOLISM; LYSIS; MALE; MULTICENTER STUDY; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT; REVIEW; SINGLE BLIND PROCEDURE; SURVIVAL RATE;

EID: 0027725185     PISSN: 08975957     EISSN: 15273466     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1993.tb00193.x     Document Type: Article

References (38)

1. A linear ammo acid sequence involved in the interaction of t‐PA with its endothelial cell receptor
2. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction
3. Thrombolysis with human extrinsic (tissue‐type) plasminogen activator in rabbits with experimental jugular vein thrombosis
4. Absence of synergism between tissue‐type plasminogen activator (t‐PA), single‐chain urokinase‐type plasminogen activator (scu‐PA) and urokinase on clot lysis in a plasma milieu in vitro
5. Comparative properties of two clinical preparations of recombinant human tissue‐type plasminogen activator in patients with acute myocardial infarction
6. effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
7. Thrombolytic therapy for acute myocardial infarction—a review
8. The endothelial cell tissue plasminogen activator receptor
9. A comparison between heparin and low‐dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction
10. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction
11. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t‐PA deletion variant BM 06.022
12. Serpin‐resistant mutants of human tissue‐type plasminogen activator
13. Thrombolysis with an Escherichia coli‐produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis
14. Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model
15. Pharmacokinetic properties of an Escherichia coli‐produced recombinant plasminogen activator (BM 06.022) in rabbits
16. Dose‐ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers,
17. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers
18. Heparin and systemic lysis maintain coronary blood flow after reperfusion by BM 06.022 in dogs
19. Pharmacokinetics of the novel recombinant plasminogen activator BM 06.022 in rats, dogs, and non‐human primates
20. Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis
21. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase, and urokinase in a canine model of coronary artery thrombosis
22. Hirudin and sulotroban improve coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary artery thrombosis
23. Pharmacokinetics and effects on the hemostatic system of bolus application of a novel recombinant plasminogen activator in AMI patients
24. Dose‐ranging study of a novel recombinant plasminogen activator in patients with acute myocardial infarction: results of the GRECO study
25. Consequences of recclusion after successful reperfusion therapy in acute myocardial infarction
26. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti‐thrombotic agents
27. Pharmacokinetics of antigen and activity of recombinant tissue‐type plasminogen activator after infusion in healthy volunteers
28. Influence of a novel recombinant plasminogen activator BM 06.022 on the hemostatic system: dose‐ranging multicenter study (GRECO)
29. Binding of recombinant variants of tissue‐type plasminogen activator (t‐PA) to human umbilical vein endothelial cells
30. Mapping of the catalytic site of CHO‐t‐PA and the t‐PA variant BM 06.022 by synthetic inhibitors and substrates
31. On the interaction of the finger and the kringle 2 domain of tissue‐type plasminogen activator with fibrin
32. Double bolus r‐PA in the dosage finding. Results of the GRECO II study (Abstr)
33. Functional properties of the recombinant kringle 2 domain of tissue plasminogen activator produced in